Vernalis plc, of Winnersh, UK, said results from its phase II proof-of-concept study of fatty acid amide hydrolase inhibitor V158866 failed to meet the primary endpoint of pain reduction in patients with neuropathic pain resulting from spinal cord injury. Read More
Beigene Ltd., of Beijing, has established its first good manufacturing practices-certified manufacturing facility for commercial use at Biobay in the Suzhou Industrial Park in Suzhou, China. Read More
Nemus Bioscience Inc., of Costa Mesa, Calif., said it entered a securities purchase agreement for the sale of 5,000 shares of series B convertible preferred stock and warrants to purchase 6.25 million shares of common stock for gross proceeds of $5 million. Read More
NEW DELHI – India's Lee Pharma Ltd. may not be granted a compulsory license to manufacture a patented diabetes drug, with the patent regulator suggesting the company has not made a strong enough case for such a license. Read More
An attempt to dissect asthma subtypes has led to the unexpected conclusion that two such subtypes, though characterized by the involvement of different types of helper T cells, may be interrelated. Read More
For personalized medicine to deliver on its promise of tailoring treatments to the patient, incentives may be needed to spur the development of diagnostics that can identify those who would benefit from a specific drug. Read More
Macrocure Ltd. shares (NASDAQ:MCUR) hit an all-time low on Thursday after a futility analysis of partial data from a pivotal phase III study revealed that the company's sole candidate, the cell therapy Curexcell, is unlikely to meet its primary endpoint of helping heal venous leg ulcers (VLU) faster than a placebo, leaving the company without one of the key trials expected to underpin an FDA biologics license application planned for the second half of 2016. Read More
